Ongoing research aims to develop more targeted antimitotic agents with reduced toxicity profiles. Advances in pharmacogenomics hold promise for personalized medicine approaches, allowing for the tailoring of antimitotic therapy based on an individual's genetic makeup. This could potentially minimize adverse effects and improve therapeutic outcomes. Furthermore, the development of agents that specifically target cancer cell-specific pathways offers a promising avenue for reducing the toxicity associated with traditional antimitotic agents.
